ReviewMicrobiome2024
Gut microbiome and cardiometabolic comorbidities in people living with HIV.
Review in Microbiome, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Insights into Microbiota-Vaccine Crosstalk in Humans: Mechanisms, Modulators, and Translational Horizons.Vaccines · 2026Review
- Elevated Serum Lipopolysaccharides and Intrinsic Factor Autoantibodies Correlate With Macrocytic Anemia Among People With HIV.Immunity, inflammation and disease · 2026Article
- Gut feelings and sweet teeth: nutritional solutions to the gut damage in inflammatory bowel disease and HIV infection.Frontiers in nutrition · 2026Review
- Integrase inhibitor-based antiretroviral therapy drives gut microbiota remodeling and immune recovery in HIV infection.Frontiers in medicine · 2026Article
- The potential role of trained immunity in HIV-associated atherosclerotic cardiovascular disease: mechanisms and therapeutic implications.Frontiers in immunology · 2026Review
- Residual HIV activity and host immunometabolic remodeling during antiretroviral therapy: implications for cardiovascular-kidney-metabolic risk.Frontiers in immunology · 2026Review
- HIV-Associated Lymphomas: Updates from Pathogenesis to Treatment Strategies.Current HIV research · 2026Review
- Abnormal characteristics of intestinal microenvironment in HIV immunological non-responders.Frontiers in immunology · 2026Review
- Association of gut microbiota and inflammation with carotid atherosclerosis in HIV infection with poor immune reconstitution.Frontiers in immunology · 2026Article
- The Impact of Gut Microbial Metabolomics on Type 2 Diabetes Development in People Living with HIV.Metabolites · 2025Review
- Gut microbiota-associated non-cholesterol sterol dysregulation modulates immune reconstitution during antiretroviral therapy in people living with HIV.Microbiology spectrum · 2025Article
- "Sometimes They Exclude Us because of Our Age-That's Not Right": Perceptions of HIV Cure Research Among Diverse Long-Term Survivors in the United States.AIDS research and human retroviruses · 2025Article
- Patterns of immune recovery in people living with HIV who initiated antiretroviral therapy as late presenters.BMC infectious diseases · 2025Article
- Mapping the Gut Microbiota Composition in the Context of Raltegravir, Dolutegravir, and Bictegravir-A Scoping Review.International journal of molecular sciences · 2025Article
- The heart of the matter: modeling HIV-associated cardiovascular comorbidities in nonhuman primate models.Frontiers in cellular and infection microbiology · 2025Review
- Pathobiology of HIV-related metabolic and cardiovascular comorbidities: Towards a unifying mechanism.African journal of laboratory medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundDespite modern antiretroviral therapy (ART), people living with HIV (PLWH) have increased relative risk of inflammatory-driven comorbidities, including cardiovascular disease (CVD). The gut microbiome could be one of several driving factors, along with traditional risk factors and HIV-related risk factors such as coinfections, ART toxicity, and past immunodeficiency.
resultsPLWH have an altered gut microbiome, even after adjustment for known confounding factors including sexual preference. The HIV-related microbiome has been associated with cardiometabolic comorbidities, and shares features with CVD-related microbiota profiles, in particular reduced capacity for short-chain fatty acid (SCFA) generation. Substantial inter-individual variation has so far been an obstacle for applying microbiota profiles for risk stratification. This review covers updated knowledge and recent advances in our understanding of the gut microbiome and comorbidities in PLWH, with specific focus on cardiometabolic comorbidities and inflammation. It covers a comprehensive overview of HIV-related and comorbidity-related dysbiosis, microbial translocation, and microbiota-derived metabolites. It also contains recent data from studies in PLWH on circulating metabolites related to comorbidities and underlying gut microbiota alterations, including circulating levels of the SCFA propionate, the histidine-analogue imidazole propionate, and the protective metabolite indole-3-propionic acid.
conclusionsDespite recent advances, the gut microbiome and related metabolites are not yet established as biomarkers or therapeutic targets. The review gives directions for future research needed to advance the field into clinical practice, including promises and pitfalls for precision medicine. Video Abstract.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.